Y-mAbs Therapeutics (NASDAQ:YMAB) is a clinical‐stage biopharmaceutical company dedicated to the development and commercialization of novel antibody‐based therapies for pediatric oncology and rare diseases. The company’s pipeline centers on monoclonal antibodies and radioimmunoconjugates designed to target tumor‐associated antigens, with a focus on high‐risk neuroblastoma and other aggressive malignancies affecting children. Through a combination of proprietary discovery platforms and strategic partnerships, Y-mAbs seeks to address unmet medical needs by leveraging precision immunotherapy approaches.
The company’s lead product, naxitamab‐gqgk (Danyelza), received accelerated approval from the U.S. Food and Drug Administration for the treatment of relapsed or refractory high-risk neuroblastoma, marking a significant milestone in pediatric cancer care. In addition to its commercial offering in the United States, Y-mAbs is advancing omburtamab (Omlonti), a radioimmunotherapy targeting B7-H3, through late‐stage clinical trials. Earlier‐stage programs include antibody candidates directed at central nervous system and solid tumors, as well as select rare disease indications, supporting a diversified portfolio aligned with the company’s mission.
Founded in 2014 as a spin-out from Memorial Sloan Kettering Cancer Center, Y-mAbs maintains its global headquarters in New York City with research and development operations in Belgium. The company’s international footprint facilitates clinical trial enrollment across North America and Europe, while engaging with regulatory authorities to expand market access for its therapies. Y-mAbs collaborates with academic institutions and industry partners to enrich its pipeline and accelerate the translation of laboratory discoveries into clinical benefit.
Y-mAbs is led by President and Chief Executive Officer Claudius Gotfreund, a seasoned executive with deep expertise in antibody development and oncology drug commercialization. Supported by a leadership team that includes experienced professionals in clinical operations, regulatory affairs and manufacturing, the company remains focused on advancing its late-stage candidates toward approval and delivering new treatment options to patients with limited therapeutic alternatives.
